CA3194875A1 - Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique - Google Patents

Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique

Info

Publication number
CA3194875A1
CA3194875A1 CA3194875A CA3194875A CA3194875A1 CA 3194875 A1 CA3194875 A1 CA 3194875A1 CA 3194875 A CA3194875 A CA 3194875A CA 3194875 A CA3194875 A CA 3194875A CA 3194875 A1 CA3194875 A1 CA 3194875A1
Authority
CA
Canada
Prior art keywords
peptoid
peptoids
independently
pain
trip8b
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3194875A
Other languages
English (en)
French (fr)
Inventor
Jerome Busserolles
Emmanuel Bourinet
Claude TAILLEFUMIER
Olivier Roy
Lionel NAUTON
Youssef AISSOUNI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
University of Montpellier
Université Clermont Auvergne
Sigma Clermont
Original Assignee
Centre National de la Recherche Scientifique
Institut National de la Santé et de la Recherche Médicale
University of Montpellier
Université Clermont Auvergne
Sigma Clermont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, University of Montpellier, Université Clermont Auvergne, Sigma Clermont filed Critical Centre National de la Recherche Scientifique
Publication of CA3194875A1 publication Critical patent/CA3194875A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3194875A 2020-10-06 2021-09-30 Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique Pending CA3194875A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FRFR2010186 2020-10-06
FR2010186A FR3114739B1 (fr) 2020-10-06 2020-10-06 Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique
PCT/FR2021/051694 WO2022074313A1 (fr) 2020-10-06 2021-09-30 Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique

Publications (1)

Publication Number Publication Date
CA3194875A1 true CA3194875A1 (fr) 2022-04-14

Family

ID=74553909

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3194875A Pending CA3194875A1 (fr) 2020-10-06 2021-09-30 Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique

Country Status (8)

Country Link
US (1) US20230374067A1 (enExample)
EP (1) EP4225295B1 (enExample)
JP (1) JP7853288B2 (enExample)
CN (1) CN116744957A (enExample)
CA (1) CA3194875A1 (enExample)
ES (1) ES3005857T3 (enExample)
FR (1) FR3114739B1 (enExample)
WO (1) WO2022074313A1 (enExample)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60100055T2 (de) * 2001-03-21 2003-07-24 Schwarz Pharma Ag Neue Verwendung einer Klasse von Peptidverbindungen zur Behandlung von Allodynie oder andere Arten von chronischen oder Phantomschmerzen
KR20080038408A (ko) * 2005-08-18 2008-05-06 쉬바르츠파르마에이지 근육통 치료를 위한 펩티드 화합물의 신규한 용도
EP2289886A1 (en) * 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer Peptoid agonists of nerve growth factor and their use as medicaments
US9216210B2 (en) * 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
JP7120927B2 (ja) * 2016-06-07 2022-08-17 江蘇恒瑞医薬股▲ふん▼有限公司 フェニルプロパンアミド誘導体ならびにそれらの製造方法および医薬用途
US11753432B2 (en) * 2017-01-27 2023-09-12 Academia Sinica Compound with analgesic effect for use in prevention and treatment of pain

Also Published As

Publication number Publication date
US20230374067A1 (en) 2023-11-23
EP4225295B1 (fr) 2024-11-13
JP7853288B2 (ja) 2026-04-28
EP4225295C0 (fr) 2024-11-13
CN116744957A (zh) 2023-09-12
EP4225295A1 (fr) 2023-08-16
ES3005857T3 (en) 2025-03-17
WO2022074313A1 (fr) 2022-04-14
JP2023544842A (ja) 2023-10-25
FR3114739B1 (fr) 2022-08-26
FR3114739A1 (fr) 2022-04-08

Similar Documents

Publication Publication Date Title
CA2821009C (en) Cyclosporine analogue molecules modified at amino acid 1 and 3
CH628324A5 (fr) Procede de preparation de pseudopeptides utiles comme medicaments.
JP7241019B2 (ja) Ｓｃｎ９ａアンチセンス鎮痛剤
JP2014505035A5 (enExample)
KR20020092951A (ko) 카할라이드 화합물
Stromgaard et al. Recent advances in the medicinal chemistry of polyamine toxins
EP0457701B1 (fr) Nouveaux dérivés de médiateurs endogènes, leurs sels, procédé de préparation, applications, et compositions les renfermant
JP2003508512A (ja) 非ペプチド性サイクロフィリン結合化合物とその用途
US20050090449A1 (en) Novel statine derivatives for the treatment of Alzheimer's disease
US20250179119A1 (en) Cyclic peptide or salt thereof, and mdmx inhibitor
Chignen Possi et al. Influences of histidine-1 and azaphenylalanine-4 on the affinity, anti-inflammatory, and antiangiogenic activities of azapeptide cluster of differentiation 36 receptor modulators
EP4225295B1 (fr) Nouveaux peptoides et leur utilisation dans la prevention ou le traitement de la douleur chronique
WO2012149218A2 (en) Antagonists of trpv1 receptor
WO2002096934A1 (en) Non-natural galanin receptor ligands
FR2830016A1 (fr) Compositions pour la vectorisation de derives taxoides a travers la barriere hematoencephalique et leur utilisation pour le traitement des cancers, plus particulierement des cancers du cerveau
CA2388663A1 (fr) Utilisation des acides quinique, shikimique et de leurs derives pour la preparation de ligands du recepteur du mannose
EP3156411B1 (en) Artificial catalyst system capable of substituting for in vivo acylation function
EP4578868A1 (en) Cyclic peptide or salt thereof, and mdmx inhibitor
EP2486007B1 (fr) Modulateurs peptidiques et peptidomimetiques non competitifs specifiques de la glycoproteine p
JP2019524673A (ja) 新規な環状ペプチドおよびその使用
García Myotoxin 3, a peptide from Crotalus oreganus rattlesnake venom as a microtubule-targeting agent
HK40129651A (en) Oxadiazole derivative compounds, and the pharmaceutical composition comprising the same
Wan Synthesis of β, γ-diamino acids and their use to design new analogues of the antimicrobial peptide Gramicidin Septide antimicrobien, la Gramicidine S
FR2785613A1 (fr) Conotoxine isolee a partir du venin de conus ermineus, ses analogues et ses applications
WO2003018618A2 (de) Katalyse der cis-trans isomerisierung von sekundären-amid peptidverbindungen

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240920

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240920

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240920

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20241218

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20250923

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250923

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250926

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250926

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251124

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20251124

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251124